دورية أكاديمية
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies.
| العنوان: | Non-small cell lung cancer: an update on emerging EGFR-targeted therapies. |
|---|---|
| المؤلفون: | Favorito V; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Ricciotti I; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., De Giglio A; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Fabbri L; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Seminerio R; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Di Federico A; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Gariazzo E; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy., Costabile S; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy., Metro G; Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy. |
| المصدر: | Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2024 Jun; Vol. 29 (2), pp. 139-154. Date of Electronic Publication: 2024 Apr 08. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101135662 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-7623 (Electronic) Linking ISSN: 14728214 NLM ISO Abbreviation: Expert Opin Emerg Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London, UK : Ashley Publications Ltd. |
| مواضيع طبية MeSH: | Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , ErbB Receptors*/genetics , ErbB Receptors*/antagonists & inhibitors , Molecular Targeted Therapy* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/administration & dosage , Mutation* , Protein Kinase Inhibitors*/pharmacology , Protein Kinase Inhibitors*/administration & dosage , Drug Resistance, Neoplasm*, Humans ; Drug Development ; Neoplasm Staging ; Animals |
| مستخلص: | Introduction: Current research in EGFR-mutated NSCLC focuses on the management of drug resistance and uncommon mutations, as well as on the opportunity to extend targeted therapies' field of action to earlier stages of disease. Areas Covered: We conducted a review analyzing literature from the PubMed database with the aim to describe the current state of art in the management of EGFR-mutated NSCLC, but also to explore new strategies under investigation. To this purpose, we collected recruiting phase II-III trials registered on Clinicaltrials.govand conducted on EGFR-mutated NSCLC both in early and advanced stage. Expert Opinion: With this review, we want to provide an exhaustive overview of current and new potential treatments in EGFR-mutated NSCLC, with emphasis on the most promising newly investigated strategies, such as association therapies in the first-line setting involving EGFR-TKIs and chemotherapy (FLAURA2) or drugs targeting different driver pathways (MARIPOSA). We also aimed at unearthing challenges to achieve in this field, specifically the need to fully exploit already available compounds while developing new ones, the management of new emerging toxicities and the necessity to improve our biological understanding of the disease to design trials with a solid scientific rationale and to allow treatment personalization such in case of uncommon mutations. |
| فهرسة مساهمة: | Keywords: EGFR; non-small cell lung cancer; osimertinib; resistance mechanisms; uncommon mutations |
| المشرفين على المادة: | EC 2.7.10.1 (ErbB Receptors) 0 (Antineoplastic Agents) 0 (Protein Kinase Inhibitors) EC 2.7.10.1 (EGFR protein, human) |
| تواريخ الأحداث: | Date Created: 20240404 Date Completed: 20240621 Latest Revision: 20240621 |
| رمز التحديث: | 20240622 |
| DOI: | 10.1080/14728214.2024.2331139 |
| PMID: | 38572595 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-7623 |
|---|---|
| DOI: | 10.1080/14728214.2024.2331139 |